VVTMF (VVT Med) LT-Debt-to-Total-Asset: 0.31 (As of Sep. 2025)


VVTMF VVT Med Inc VVTMF
6 GF Score
Price $0.02
! 4 Warning Signs
View Full Analysis

What is VVT Med LT-Debt-to-Total-Asset?

VVT Med VVTMF 6 LT-Debt-to-Total-Asset is 0.31 as of Sep. 2025. GuruFocus rates VVTMF with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. VVT Med's long-term debt to total assests ratio for the quarter that ended in Sep. 2025 was 0.31.

VVT Med's long-term debt to total assets ratio increased from Sep. 2024 (0.00) to Sep. 2025 (0.31). It may suggest that VVT Med is progressively becoming more dependent on debt to grow their business.

VVT Med  (OTCPK:VVTMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

VVT Med LT-Debt-to-Total-Asset Related Terms

VVT Med LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for VVT Med's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VVT Med LT-Debt-to-Total-Asset Chart

VVT Med Annual Data
Trend Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
0.81 1.80 0.67

VVT Med Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only 0.00 0.67 0.71 0.55 0.31
VVTMF
6GF Score
VVT Med Inc VVTMF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VVT Med LT-Debt-to-Total-Asset Calculation

VVT Med's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=0.656/0.985
=0.67

VVT Med's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (Q: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2025 )/Total Assets (Q: Sep. 2025 )
=0.59/1.931
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.31 mean?
VVT Med (VVTMF) has a LT-Debt-to-Total-Asset of 0.31 as of Sep. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on VVT Med and its competitors.
Is VVT Med's LT-Debt-to-Total-Asset too high?
VVT Med's current LT-Debt-to-Total-Asset is 0.31. Overall, VVT Med has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VVT Med's LT-Debt-to-Total-Asset compare to ABT and SYK?
VVT Med's LT-Debt-to-Total-Asset of 0.31 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on VVT Med and its competitors. VVT Med's current LT-Debt-to-Total-Asset is 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (VVTMF) has a current LT-Debt-to-Total-Asset of 0.31. The current LT-Debt-to-Total-Asset is 0.31. VVT Med's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For VVT Med (VVTMF), the current LT-Debt-to-Total-Asset is 0.31 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VVT Med Business Description

Other Exchanges VVTM:Canada
Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
6GF Score

Get the complete analysis for VVTMF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price